Share on StockTwits

Research analysts at Stifel Nicolaus boosted their price target on shares of Medivation (NASDAQ:MDVN) from $83.00 to $89.00 in a report released on Friday. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 18.24% from the stock’s previous close.

Shares of Medivation (NASDAQ:MDVN) opened at 75.27 on Friday. Medivation has a one year low of $48.15 and a one year high of $88.20. The stock’s 50-day moving average is $75.76 and its 200-day moving average is $71.52. The company’s market cap is $5.760 billion.

Medivation (NASDAQ:MDVN) last announced its earnings results on Thursday, August 7th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.36. The company had revenue of $148.09 million for the quarter, compared to the consensus estimate of $126.46 million. During the same quarter in the previous year, the company posted ($0.07) earnings per share. The company’s revenue for the quarter was up 111.1% on a year-over-year basis. On average, analysts predict that Medivation will post $1.50 earnings per share for the current fiscal year.

A number of other analysts have also recently weighed in on MDVN. Analysts at Brean Capital raised their price target on shares of Medivation from $100.00 to $105.00 in a research note on Friday. They now have a “buy” rating on the stock. Separately, analysts at Credit Suisse raised their price target on shares of Medivation from $95.00 to $98.00 in a research note on Monday. They now have an “outperform” rating on the stock. Finally, analysts at Aegis reiterated a “buy” rating on shares of Medivation in a research note on Wednesday, July 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $94.00.

Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.

Receive News & Ratings for Medivation Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivation Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.